Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
about
Tamoxifen induces expression of immune response-related genes in cultured normal human mammary epithelial cellsIdentification of cytoplasmic proteins interacting with unliganded estrogen receptor α and β in human breast cancer cellsEstrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAsDifferential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cellsEstradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cellsCooperating transcription factors mediate the function of estrogen receptorThe p53-estrogen receptor loop in cancerMet kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survivalIncreased 14-3-3ζ expression in the multidrug-resistant leukemia cell line HL-60/VCR as compared to the parental line mediates cell growth and apoptosis in part through modification of gene expressionCytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell deathOverexpression of YWHAZ relates to tumor cell proliferation and malignant outcome of gastric carcinomaTwo estrogen response element sequences near the PCNA gene are not responsible for its estrogen-enhanced expression in MCF7 cellsIdentification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβIntegration of molecular profiling and chemical imaging to elucidate fibroblast-microenvironment impact on cancer cell phenotype and endocrine resistance in breast cancerAmplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancersMechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.ERbeta in breast cancer--onlooker, passive player, or active protector?Integrating text mining, data mining, and network analysis for identifying genetic breast cancer trendsComparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovariectomized mice.Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection.BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database.Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism.Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.Estrogen coordinates translation and transcription, revealing a role for NRSF in human breast cancer cells.Meta-analysis of estrogen response in MCF-7 distinguishes early target genes involved in signaling and cell proliferation from later target genes involved in cell cycle and DNA repair.Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.14-3-3ζ as a prognostic marker and therapeutic target for cancerGenomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs.High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy.Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sitesThe stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells.The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cellsEstrogen receptor β ligands: recent advances and biomedical applications.Estrogen increases secretion of stromal cell derived factor-1 in human breast cancer cells.Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers.14-3-3 proteins as potential therapeutic targets.Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
P2860
Q23916703-854D75CC-852B-446F-B849-5B0AF5649AA9Q24315496-1A80292D-FB19-4B7E-AB93-576968378999Q24631037-32DF4663-A872-4723-BC1E-FF10C837A109Q24641991-DD85BE4D-A6C7-4CCB-8502-54BDF42CA047Q24649539-D6D3F85F-8327-4DC6-9E73-4413E11D578AQ26996464-F3C1AAC9-D8E9-4CCA-AA66-46FB5893D189Q27027865-DCCB2FC1-E7D1-46D8-8865-F00054BEF19DQ27316936-2813FFC7-FE33-419A-85AC-1BF9D57DA8DBQ28235429-A9653F68-909C-4FB1-8759-E75C28F5D7BDQ28259195-44A1D259-9F32-4E2D-B18D-7692141E28A6Q28285857-186AA084-BF8B-47B9-891C-4786A27EB5B0Q28473885-496BF6E8-3D9A-440F-8E83-343C2CF8E3B4Q28480546-0C254A71-9E36-4568-8411-864E62809F12Q28538685-76431BA6-39B3-414F-8C45-8C4B27D72996Q28728499-E41D7297-07B5-41CE-B241-CCD194FF80E3Q30436239-D21BD73A-BE44-45F7-8841-950C71A7ED43Q30438399-B378D7DC-5811-402B-8C14-7AF99BB04A64Q31084513-19654C35-FC78-4304-8348-D38293EC7A29Q33287050-9651DAA5-6AFE-4E0E-A037-E99CBCB1260DQ33576510-4B5EC6F8-845B-479F-8283-DB046D59164CQ33643334-32FAC5D3-D32A-4B61-8994-24A25DFC31EFQ33739680-4EB78C92-C593-4793-AE30-25A6F55D756FQ33739866-B7CE89BB-65A2-4DA7-9494-385501D7B76CQ33874316-59AC269C-761D-47D0-9A89-AE0D9DEB0E62Q34005895-29AF1117-BD01-4E9F-9138-8DA0EA557D57Q34374852-D6B1B3F8-7407-435C-A2B4-5925C45A22C2Q34411166-B60ABD0B-0324-4D32-A678-06C8D03576B6Q34473399-0883D2F2-5128-4CFD-A034-DAB28FB1C634Q34484372-14044AC4-94DE-4C90-990A-A8B7728087A2Q34549892-44A1D86B-37E5-4839-A829-981E6DF4F8EBQ34682354-9021EF6E-12C7-40DD-AFAF-C483BFE5ADB1Q34856382-A7E638FE-A5DD-4923-A283-D6B6DBA7F6D7Q35000256-8EEC8694-E3F4-4AB9-9D49-58F19FA4B574Q35016384-27B4DE58-3F9B-4006-BD44-36F796D982E9Q35017260-A708C938-5009-4EAD-A59E-458DE7D735B5Q35218111-9A41CFF9-645E-47BC-8E90-5537B0699DBFQ35497722-6D0AFDAF-406E-478E-B62B-F308B60B28A0Q35510924-87867BF9-D1D0-4ED9-AA26-E5AB7DDD4111Q35545816-BC97AC0A-D15E-4579-8E75-20BA30E4CAF4Q35558134-0F27949C-D77F-43E4-B434-071A028CD05F
P2860
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Gene expression preferentially ...... lations with clinical outcome.
@en
type
label
Gene expression preferentially ...... lations with clinical outcome.
@en
prefLabel
Gene expression preferentially ...... lations with clinical outcome.
@en
P2093
P50
P1433
P1476
Gene expression preferentially ...... lations with clinical outcome.
@en
P2093
Barry Komm
Edison T Liu
Edmund C Chang
Johanna Smeds
Jonas Bergh
Jonna Frasor
Vinsensius B Vega
P304
P356
10.1158/0008-5472.CAN-05-4269
P407
P577
2006-07-01T00:00:00Z